Lixumistat is ImmunoMet's lead compound, a selective OxPhos inhibitor with a safety profile appropriate for further development. Lixumistat's anti-cancer potential was originally investigated in patients with advanced solid tumors (NCT03272256) and more recently in advanced cancer patients (NCT05497778). Additionally, the safety, pharmacokinetics, pharmacodynamics, and potential effect of food on pharmacokinetics were characterized in healthy subjects.
All study data verified from investor materials. NCT numbers confirmed. GBM window-of-opportunity study confirmed.
An orally administered small-molecule biguanide with robust in vitro activity and in vivo efficacy across selected cancers. It is the first PC1 inhibitor to demonstrate target engagement in humans at tolerable doses and define a recommended Phase 2 dose. Importantly, lixumistat demonstrated robust clinical activity in patients with advanced pancreatic cancer.
Lixumistat's mechanism applies anywhere disease becomes OxPhos-dependent. See the investment case or talk to our team.
